EO 2040
Alternative Names: EO-2040Latest Information Update: 28 Mar 2024
At a glance
- Originator Enterome
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 31 Dec 2023 Enterome completes phase II CLAUDE clinical trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Germany and USA (Parenteral) (NCT05350501) (EudraCT2022-002679-12)
- 14 Jun 2023 Enterome initiates enrolment in a phase-II clinical trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral) (NCT05350501)
- 24 Mar 2023 Phase-II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (Parenteral) (NCT05350501) (EudraCT2022-002679-12)